{"id":"W4319826851","doi":"10.1182/bloodadvances.2022008866","title":"Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb; Amgen","keywords":"Daratumumab; Medicine; Carfilzomib; Pomalidomide; Internal medicine; Multiple myeloma; Confidence interval; Dexamethasone; Oncology; Lenalidomide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002581518,0.001806946,0.002673284,0.0006071236,0.0005154958,0.0007645062,0.001015158,0.00133053,0.002168381],"category_scores_gemma":[0.001163858,0.0009211777,0.001299686,0.0004229205,0.001290395,0.0008534245,0.0003348489,0.00376058,0.0005863048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007716762,"about_ca_system_score_gemma":0.001620619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008671647,"about_ca_topic_score_gemma":0.002145046,"domain_scores_codex":[0.9991294,0.0004788786,0.00003785798,0.0001345163,0.0001033348,0.0001160501],"domain_scores_gemma":[0.9992478,0.0001376136,0.0001363953,0.00007088335,0.00004305115,0.0003643472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6182066,0.1981926,0.00689764,0.0006644076,0.001079317,0.0005818958,0.000449761,0.002402893,0.06815149,0.0003147876,0.002602029,0.1004566],"study_design_scores_gemma":[0.5498725,0.4376576,0.006016142,0.00001794231,0.0002793748,0.0002497257,0.0000345236,0.0008050886,0.003318794,0.0001091183,0.001611567,0.00002756959],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939021,0.002298225,0.0003962363,0.0004440079,0.0001456759,0.001757814,0.0003554401,0.00006413527,0.0006363159],"genre_scores_gemma":[0.9876857,0.002024311,0.002665262,0.001119754,0.0003935786,0.003070223,0.001019204,0.00003485223,0.001987122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002673284,"threshold_uncertainty_score":0.01365256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02775344379533928,"score_gpt":0.3433425223205218,"score_spread":0.3155890785251825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}